GOBBI, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 89
EU - Europa 52
AS - Asia 30
AF - Africa 3
Totale 174
Nazione #
US - Stati Uniti d'America 89
GB - Regno Unito 23
SG - Singapore 13
CN - Cina 12
DE - Germania 9
IT - Italia 5
IN - India 4
IE - Irlanda 3
SE - Svezia 3
EE - Estonia 2
FR - Francia 2
UA - Ucraina 2
BG - Bulgaria 1
CH - Svizzera 1
CI - Costa d'Avorio 1
JO - Giordania 1
RU - Federazione Russa 1
TG - Togo 1
ZA - Sudafrica 1
Totale 174
Città #
Southend 23
Fairfield 17
Woodbridge 15
Singapore 13
Seattle 10
Houston 8
Wilmington 8
Ashburn 6
Cambridge 6
Princeton 4
Ann Arbor 3
Dublin 3
Nanjing 3
Shenyang 2
Turin 2
Westminster 2
Abidjan 1
Amman 1
Berlin 1
Chandler 1
Changsha 1
Fremont 1
Hebei 1
Hefei 1
Krefeld 1
Lanzhou 1
Lausanne 1
Lomé 1
Milan 1
Nanchang 1
Nuremberg 1
Padova 1
Perugia 1
Sofia 1
Taiyuan 1
Zhengzhou 1
Totale 145
Nome #
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study 84
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 73
Chronic lymphocytic leukemia: prognostic factors and stage classification (author's transl) 15
B-b10 (Anti-CD25)-saporin immunotoxin—a possible tool in graft-versus-host disease treatment1 8
An epstein-barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins 3
Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation 2
Totale 185
Categoria #
all - tutte 680
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 680


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202069 0 2 0 1 10 8 11 11 13 3 5 5
2020/202121 7 4 2 0 0 1 1 0 4 0 0 2
2021/202224 1 2 2 1 3 2 1 1 1 1 6 3
2022/202325 2 1 0 4 1 1 2 0 7 1 3 3
2023/202412 1 0 1 2 0 1 0 5 0 2 0 0
2024/202514 10 4 0 0 0 0 0 0 0 0 0 0
Totale 185